Actualización sobre el manejo de los tumores de la médula espinal: nuevas herramientas terapéuticas
Palabras clave:
Spinal Cord, Spinal Cord Neoplasms, TherapeuticsResumen
sin resumen
Descargas
Citas
1. Ali AMS, Mustafa MA, Ali OME, Gillespie CS, Richardson GM, Clark S, et al. Patient-reported outcomes in primary spinal intradural tumours: a systematic review. Spinal Cord. 2024;62(6):275-4. DOI: https://doi.org/10.1038/s41393-024-00987-6
2. Beall DP, Googe DJ, Emery RL, Thompson DB, Campbell SE, Ly JQ, et al. Extramedullary intradural spinal tumors: a pictorial review. Curr Probl Diagn Radiol. 2007;36(5):185-98. DOI: https://doi.org/10.1067/j.cpradiol.2006.12.002
3. Azad TD, Jiang B, Bettegowda C. Molecular foundations of primary spinal tumors-implications for surgical management. Ann Transl Med. 2019;7(10):222. DOI: https://doi.org/10.21037/atm.2019.04.46
4. Purvis TE, Goodwin CR, Lubelski D, Laufer I, Sciubba DM. Review of stereotactic radiosurgery for intradural spine tumors. CNS Oncol. 2017;6(2):131-8. DOI: https://doi.org/10.2217/cns-2016-0039
5. Abd-El-Barr MM, Huang KT, Moses ZB, Iorgulescu JB, Chi JH. Recent advances in intradural spinal tumors. Neuro Oncol. 2018;20(6):729-42. DOI: https://doi.org/10.1093/neuonc/nox230
6. Liu S, Yang J, Jin H, Liang A, Zhang Q, Xing J, et al. Exploration of the application of augmented reality technology for teaching spinal tumor’s anatomy and surgical techniques. Front Med. 2024;11:7-8. DOI: https://doi.org/10.3389/fmed.2024.1403423
7. Baig Mirza A, Gebreyohanes A, Knight J, Bartram J, Vastani A, Kalaitzoglou D, et al. Prognostic factors for surgically managed intramedullary spinal cord tumours: a single-centre case series. Acta Neurochir (Wien). 2022;164(10):2605-22. DOI: https://doi.org/10.1007/s00701-022-05304-9
8. Kringel R, Lamszus K, Mohme M. Chimeric Antigen receptor T Cells in glioblastoma-current concepts and promising future. Cells. 2023;12(13):7-8. DOI: https://doi.org/10.3390/cells12131770
9. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65. DOI: https://doi.org/10.1056/nejmoa1200694
10. Ropper AE, Zeng X, Haragopal H, Anderson JE, Aljuboori Z, Han I, et al. Targeted treatment of experimental spinal cord glioma with dual gene-engineered human neural stem cells. Neurosurg. 2016;79(3):481-91. DOI: https://doi.org/10.1227/neu.0000000000001174
11. Oishi T, Koizumi S, Kurozumi K. Mesenchymal stem cells as therapeutic vehicles for glioma. Cancer Gene Ther. 2024;38654128. DOI: https://doi.org/10.1038/s41417-024-00775-7
12. Mitsuya K, Akiyama Y, Iizuka A, Miyata H, Deguchi S, Hayashi N, et al. Alpha-type-1 polarized dendritic cell-based vaccination in newly diagnosed high-grade glioma: A phase II clinical trial. Anticancer Res. 2020;40(11):6473-84. DOI: https://doi.org/10.21873/anticanres.14669
13. Zhang X, Shao X, Bao Q, He L, Qi X. Integrated network pharmacology and experimental verification to reveal the role of Shezhi Huangling Decoction against glioma by inactivating PI3K/Akt-HIF1A axis. Heliyon. 2024;10(14):7-8. DOI: https://doi.org/10.1016/j.heliyon.2024.e34215
14. Marima R, Basera A, Miya T, Damane BP, Kandhavelu J, Mirza S, et al. Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues. Noncoding RNA Res. 2024;9(3):887-900. DOI: https://doi.org/10.1016/j.ncrna.2024.03.014
15. Tang J, Wang X, Lin X, Wu C. Mesenchymal stem cell-derived extracellular vesicles: a regulator and carrier for targeting bone-related diseases. Cell Death Discov. 2024;10(1):7-8. DOI: https://doi.org/10.1038/s41420-024-01973-w
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Valentina González- Cárdenas, Stefanya Geraldine Bermúdez - Moyano, Juan Santiago Serna Trejos
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
